Clinical Trials Packaging Patients Topical 
Cannabis Law Report
OCTOBER 10, 2021
As a think tank we develop new ideas and concepts for providing medical cannabis to patients both in Germany and Europe. Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. Customized compensation package.
Puff Puff Post
NOVEMBER 5, 2019
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Puff Puff Post
NOVEMBER 5, 2019
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
Cannabis Law Report
NOVEMBER 10, 2021
“We are encouraged with the progress that has been made under the CRADA with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative, as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain.
Cannabis Law Report
NOVEMBER 15, 2021
We are looking forward to the completion of the required IND enabling studies and submitting our IND package to the FDA in anticipation of first-in-human trials,” continued Mr. Mack. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. On September 9, 2021, Jeffrey A.
The Cannigma
DECEMBER 22, 2021
It doesn’t mean, necessarily, that the market should go to full legalization within a year or two, because it won’t happen so fast, but you can have more patients with other medical indications that were not given cannabis before. Obviously, that means that there are more patients and there are more products to sell.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.
Expert insights. Personalized for you.
52 
Let's personalize your content